Drug Profile


Alternative Names: ABT-126

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Class Adamantanes; Aza compounds; Nootropics; Small molecules; Thiadiazoles
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders
  • Suspended Alzheimer's disease

Most Recent Events

  • 28 Jul 2015 Phase-II development is ongoing for Cognition disorders in patients with schizophrenia
  • 27 Oct 2014 AbbVie terminates long-term phase II trial in Cognition disorders in patients with schizophrenia in USA, Russia and United Kingdom (NCT01834638)
  • 01 Jul 2014 AbbVie completes a phase II trial in Cognition disorders in patients with schizophrenia in the US, Russia and the UK (NCT01655680)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top